Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice.
The systemic efficacy of the antipicornavirus agent WIN 51711 was assessed in suckling mice infected with echovirus type 9 (Barty strain). Single, daily intraperitoneal doses of WIN 51711 as low as 10 mg/kg significantly (P less than .01) slowed the rate of onset of echovirus-induced paralysis and reduced the number of paralyzed animals. Intraperitoneal administration beginning 2 hr before infection or 48 hr after infection was equally effective in preventing paralysis. Oral administration of WIN 51711 twice daily beginning 72 hr after infection was the most-effective dosage regimen, with doses as low as 3 mg/kg preventing paralysis in 75% of the animals. Titers of virus in asymptomatic mice on day 6 after infection were reduced by up to 4.75 log pfu in WIN 51711-medicated mice when compared with placebo. Maximal concentrations of WIN 51711 in adult mice after oral medication with a 100 mg/kg dose were 24.3, 21.5, 10.4, 9.8, 6.9, and 4.1 micrograms/g in heart, kidney, brain, liver, serum (micrograms/ml), and muscle, respectively at 0.5-1.0 hr after medication.
D000284:Administration, Oral; D000818:Animals; D000833:Animals, Suckling; D000998:Antiviral Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004459:Echovirus 9 / Q000187:drug effects; D004457:Echovirus Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D007274:Injections, Intraperitoneal; D007555:Isoxazoles / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D051379:Mice; D010080:Oxazoles / Q000627:therapeutic use*; D010243:Paralysis / Q000209:etiology / Q000517:prevention & control*; D014018:Tissue Distribution
D000998:Antiviral Agents; D007555:Isoxazoles; D010080:Oxazoles; C045978:disoxaril